5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.04%
Positive revenue growth while STERV.HE is negative. John Neff might see a notable competitive edge here.
-8.38%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-22.90%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.90%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-19.83%
Negative net income growth while STERV.HE stands at 3.20%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-16.67%
Negative EPS growth while STERV.HE is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-16.67%
Negative diluted EPS growth while STERV.HE is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-3.79%
Share reduction while STERV.HE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.79%
Reduced diluted shares while STERV.HE is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
401.80%
Positive OCF growth while STERV.HE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
168.23%
Positive FCF growth while STERV.HE is negative. John Neff would see a strong competitive edge in net cash generation.
-39.39%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-42.40%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-15.23%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-14.87%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
200.18%
5Y OCF/share CAGR above 1.5x STERV.HE's 17.26%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
645.27%
3Y OCF/share CAGR above 1.5x STERV.HE's 16.49%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
120.83%
Similar net income/share CAGR to STERV.HE's 119.24%. Walter Schloss would see parallel tailwinds or expansions for both firms.
145.45%
Below 50% of STERV.HE's 372.64%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
150.00%
3Y net income/share CAGR above 1.5x STERV.HE's 57.32%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
-12.34%
Negative 5Y equity/share growth while STERV.HE is at 0.74%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
17.76%
3Y equity/share CAGR above 1.5x STERV.HE's 4.52%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Firm’s AR is declining while STERV.HE shows 9.70%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-3.28%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-0.41%
Negative asset growth while STERV.HE invests at 0.83%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.38%
BV/share growth above 1.5x STERV.HE's 2.16%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-1.32%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
1.34%
We expand SG&A while STERV.HE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.